AFJOG

African Journal of Obstetrics and Gynaecology | Volume 2 | Issue 2 | 2024 | 45 African Journal of Obstetrics and Gynaecology | Volume 2 | Issue 2 | 2024 | Abstracts AFJOG ABSTRACTS this option every year. A trisomy 21 only test was introduced at the same time. Requests have been increasing every year, which is indicative of the economic pressure experienced by patients. The largest number of high-risk results was reported for trisomy 21, followed by trisomy 18, monosomy X and trisomy 13. Referrals most commonly followed after an increased-risk serum screen or it was based on advanced maternal age, but, a significant number of patients opted for NIPT with no specific concerns. As expected, the highest percentage of high-risk results were reported for ultrasound anomalies and high-risk serum screens. However, a high-risk NIPT result was reported for almost 2% of referrals based on patient concern alone. Conclusion: NIPT is highly valuable for not only decreasing the requirement for invasive tests after high-risk biochemical screening results, but also allowing for an earlier indication giving health care professionals and patients more options in managing high-risk pregnancies. Although the uptake has steadily increased over time, the high cost and low reimbursement rate is still limiting access for patients. ABSTRACTTITLE: 281: Same day HPV screen and treat: Implementation results AUTHORS: Dr Nondumiso Ngxola ndumy.ngxola@gmail.com Nondumiso Ngxola 1 1 WSU/ WHO Introduction: Sub-Saharan African countries suffer from a high burden of cervical cancer (CC) and HIV infection. Effective cervical screening and treatment is not yet widely available and there is a lack of colposcopy, histopathology, and follow-up installed capacity. We present the results of the initial implementation of the same-day screen-and-treat (with and without triage) approach for women living with HIV (WLWH) participating in the CESTA study. Methods: In CESTA (Fig.1), WLWH aged 25-54 years are screened for HPV with a clinician sample tested directly on site in one hour using GeneXpert®. HPV-positive WLWH are randomised in a 4:1 ratio into VIA triage followed by thermal ablation (TA) treatment (VIA-triage arm) or direct TA (no-triage arm). Ineligible women for TA are referred to colposcopy. Proportions of women completing the screen- and-treat or screen, triage, and treatment approach are estimated. Results: Among the 940 WLWH enrolled in the CESTA study, 934 were tested for HPV, 4 were directly referred for cancer management and 2 did not have any result (1 get invalid, the other was suspicious of cancer, but biopsy came back inconclusive). 609 of 934 women were HPV positive (prevalence 65%, 95%CI: 62-68). In the VIA-triage arm (n=484), 442 WLWH were evaluable for VIA (91%, 95%CI: 88-94, Fig. 2); VIA positivity among them was 376/442 (85%, 95%CI: 82-88). Overall, 475/609 WLWH (78%, 95%CI: 74-81) received TA the same day. Colposcopy referral was mainly due to the squamous-columnar junction not fully visible (mostly WLWH older than 44 y/o, p<0.05). 541 of 609 randomised women completed the one visit screen-and- treat algorithm approach (89%, 95%CI: 86-91). Conclusion: Same-day screen-and-treat approach is feasible, should reduce the lost to follow-up and provide ablative treatment on the same day for eligible women. However, it should be noted that a proportion of women will always be referred to colposcopy (i.e., older women, advanced disease). Finally, the high positivity of HPV DNA testing as well as visual triage on WLWH deserves further evaluation. ABSTRACTTITLE: 500: Angiogenic biomarkers distinguish between COVID and preeclampsia in pregnant South African women: Data from The COMPRESS Study AUTHORS: Prof Mushi Matjila Mushi.Matjila@uct.ac.za Mushi Matjila 1 , Georgia Schafër 2 , Ayesha Osman 1 , Jackie Chokoe-Maluleke 3 , Unathi Mooketsi 1 , Ally Oosthuizen1, Komala Pillay 3 , Dilly Anumba 4 , Nadia M. Ikumi 3 1 Department of Obstetrics and Gynaecology, University of Cape Town, Cape Town, South Africa 2 International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town, South Africa 3 Division of Anatomical Pathology, Department of Pathology, University of Cape Town. 4 Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, United Kingdom Introduction: Preeclampsia remains one of the contributors to maternal and perinatal morbidity and mortality across the world, and for most low- and middle-income countries (LMICs). Preeclampsia (PET) has been defined by the presence of hypertension (new onset or pre-existing) and significant proteinuria. However, some conditions, including the recent (SARS-CoV2) infection, renal disease, SLE and APS, have been identified as phenotypic “mimickers of preeclampsia’ due to common overlap with hypertension and/or proteinuria. Further, they may share underlying pathophysiological mechanisms with preeclampsia including hyperinflammation, endothelial dysfunction and vascular thrombosis. Placental biomarkers can be invaluable in distinguishing preeclampsia from other hypertensive disorders as well as these mimickers. We therefore conducted the COvid-19 Myocarditis and PReclampsia Echo and Serum Biomarker Study – COMPRESS during South Africa’s first wave of CoVID infection with the aim of exploring the potential of biomarkers in distinguishing overlapping clinical presentations between pregnant participants with SARS- CoV2 and Preeclampsia. Methods: The study was conducted at tertiary-level Groote Schuur Hospital, in Cape Town South Africa. COMPRESS focussed on two cohorts of pregnant women, one with participants admitted for PET and the second of participants with respiratory symptoms admitted for confirmation and/or management of SARS-CoV2. The plasma concentrations of angiogenic biomarkers markers sFlt-1, PlGF and their ratio sFlt-1/PlGF, along with cardiac biomarkers proBNP, Troponin T and CKMB were quantified by electrochemiluminescence immunoassays. The sampling for all biomarkers was